Right ventricular failure due to chronic pressure load:What have we learned in animal models since the NIH working group statement? by Borgdorff, Marinus A J et al.
  
 University of Groningen
Right ventricular failure due to chronic pressure load





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Borgdorff, M. A. J., Dickinson, M. G., Berger, R. M. F., & Bartelds, B. (2015). Right ventricular failure due to
chronic pressure load: What have we learned in animal models since the NIH working group statement?
Heart failure reviews, 20(4), 475-491. https://doi.org/10.1007/s10741-015-9479-6
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Right ventricular failure due to chronic pressure load: What have
we learned in animal models since the NIH working group
statement?
Marinus A. J. Borgdorff1,2,3 • Michael G. Dickinson2 • Rolf M. F. Berger1,2 •
Beatrijs Bartelds1,2
Published online: 13 March 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Right ventricular (RV) failure determines out-
come in patients with pulmonary hypertension, congenital
heart diseases and in left ventricular failure. In 2006, the
Working Group on Cellular and Molecular Mechanisms of
Right Heart Failure of the NIH advocated the development
of preclinical models to study the pathophysiology and
pathobiology of RV failure. In this review, we summarize
the progress of research into the pathobiology of RV failure
and potential therapeutic interventions. The picture
emerging from this research is that RV adaptation to in-
creased afterload is characterized by increased contrac-
tility, dilatation and hypertrophy. Clinical RV failure is
associated with progressive diastolic deterioration and
disturbed ventricular–arterial coupling in the presence of
increased contractility. The pathobiology of the failing RV
shows similarities with that of the LV and is marked by
lack of adequate increase in capillary density leading to a
hypoxic environment and oxidative stress and a metabolic
switch from fatty acids to glucose utilization. However, RV
failure also has characteristic features. So far, therapies
aiming to specifically improve RV function have had
limited success. The use of beta blockers and sildenafil
may hold promise, but new therapies have to be developed.
The use of recently developed animal models will aid in
further understanding of the pathobiology of RV failure
and development of new therapeutic strategies.
Keywords Pressure overload  Congenital heart
diseases  Pulmonary hypertension  Pulmonary artery
banding  MRI  Pressure–volume analysis
Abbreviations
CHD Congenital heart diseases
Ees End-systolic elastance
Eed End-diastolic elastance
ERA Endothelin receptor antagonists
FAO Fatty acid oxidation
LV Left ventricle
MCT Monocrotaline
PAB Pulmonary artery banding
PDE5 Phosphodiesterase 5
PDK Pyruvate dehydrogenase kinase
PKG Protein kinase G
PH Pulmonary hypertension
RAAS Renin-angiotensin aldosterone system
RV Right ventricle
Introduction
Right ventricular (RV) failure is a major determinant of
outcome in patients with pulmonary hypertension (PH),
corrected congenital heart diseases (CHD) and in left
ventricular failure due to ischemic heart disease [1–3].
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Improved therapies for these diseases have led to a quickly
expanding population of children and young adults at risk
of mortality due to RV failure. For example, currently over
four million adults in Europe and the USA suffer from late
effects after treatment for CHD. Despite the pivotal in-
volvement of the RV in both common and rare cardio-
vascular diseases, the mechanisms of RV failure have
historically gotten little attention. Already in 1988, Reeves
pleaded that ‘‘One must inquire how increasing pulmonary
vascular resistance results in impaired RV function’’
(Reeves, cited in [4]). However, almost 20 years later in
2006, a Working Group on Cellular and Molecular
Mechanisms of Right Heart Failure of the National Heart,
Lung and Blood Institute concluded that there was ‘‘a
paucity of basic knowledge at all levels about the RV’s
normal and pathological function’’ [5]. This observation
led to a call to the research community to develop accurate
preclinical models, to study the pathophysiology and
pathobiology of RV failure and to develop new therapeutic
strategies [5]. In this review, we summarize the research in
animal models since then into the pathophysiology and
pathobiology of RV failure and possible therapeutic
interventions.
Modeling and evaluating a unique ventricle
The right ventricle is not a mirror image left
ventricle
The RV has specific characteristics that affect the response
to abnormal loading conditions, as extensively reviewed
previously [6]. In short, firstly, the RV is derived from a
distinct set of precursor cells (as compared to the LV), the
so-called secondary heart field [7]. It is yet unknown
whether this different embryological origin affects the re-
sponse to abnormal loading conditions [8]. Secondly, the
RV is a crescent-shaped structure wrapped around the LV
that has a unique contraction pattern, which complicates
functional and volumetric analysis. Thirdly, the normal RV
is unloaded after birth. During fetal life, the RV and LV
work in parallel to support the systemic and pulmonary
circulation, but after birth, these circulations are serially
connected and the pulmonary vascular resistance, which
determines the afterload of the RV, progressively de-
creases. In patients with CHD, this unloading is often ab-
sent [9]. Fourthly, the dominant movement of the RV is
longitudinal shortening, pressing the RV-free wall against
the septum to create a bellows effect to empty into the low-
resistance pulmonary circulation [6]. Finally, in normal
adult conditions, the RV has a lower oxygen requirement as
compared with the LV and lower coronary flow that mostly
occurs during systole [10]. A comprehensive overview of
differences between the RV and LV from a clinical and
preclinical perspective was published recently [11]. In the
current paper, we present a detailed analysis of the ex-
perimental literature describing the adaptation of the right
ventricle in response to increased afterload.
Evaluation of RV function and failure
To interpret the findings in preclinical models and to
translate these to clinical practice, a definition of RV fail-
ure is necessary. Right heart failure is not an entity as such
but a continuum of disease severities and clinical symp-
toms and can be defined in congruence with previous
definitions of heart failure by Sugawa and Sunagawa [12].
Heart failure is defined as the inability to meet the re-
quirements of the metabolizing tissues of the body. RV
failure is defined accordingly, but the clinical signs and
symptoms may differ from those in LV failure [13]. The
cardinal clinical characteristics of RV failure are low (ef-
fective) cardiac output (evident in exercise intolerance,
fatigue, dyspnea and poor peripheral circulation) and fluid
retention (evident in peripheral edema, effusion and
ascites) [6, 13] (Table 1). It is therefore important, in
clinical practice but also in preclinical animal experiments,
to include these clinical signs in the assessment of RV
function or failure, in addition to functional RV
parameters.
In clinical practice, exercise capacity is used as an im-
portant guide to grade the severity of heart failure and as a
prognostic indicator. Exercise capacity in patients can be
determined by maximal cardiopulmonary exercise testing
or by voluntary exercise performance, evaluated with a
6-min walk distance. Similarly, in animal models of RV
disease, forced exercise capacity can be evaluated by a
treadmill test [14, 15] and voluntary exercise capacity by
spontaneous activity in a running wheel [8, 16, 17].
Mortality is the ultimate clinical sign of RV failure, and
survival analysis may be included in studies. However, in
animal models, other factors rather than RV failure that
might impede survival (such as pulmonary disease and/or
LV dysfunction in the monocrotaline model) should be
excluded or accounted for [18]. Once RV disease has been
characterized using clinical symptoms, exercise and/or
mortality (Table 1), the disease state can be coupled to
hemodynamic and cellular adaptation (Table 2).
Modeling RV abnormal loading conditions
To study the mechanisms of RV failure, animal models that
mimic specific diseases have been developed. The diseases
contributing to the spectrum of patients with RV failure can
be divided into three main groups: (1) patients with PH, (2)
(corrected) CHD and (3) RV failure secondary to left
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ventricular failure. Although distinct in etiology, these
diseases share in common the abnormal loading conditions
imposed on the RV, i.e., increased afterload, increased
preload or a combination of both [19]. Increased afterload
can be peripherally located, as in PH or fixed proximally as
in pulmonary stenosis. Either way, the coupling between
the RV and the pulmonary arteries is disturbed (Table 2).
To represent these chronic abnormal loading conditions
models of PH, pulmonary artery banding and/or pre-tri-
cuspid systemic-to-pulmonary shunts have been developed.
Knowledge on the RV response to an increase in preload is
scarce [16, 20, 21] and will be discussed in a separate
paper. In this review, we will focus on the response to
increased afterload.
Models of increased afterload
Historically, researchers used the monocrotaline model
(MCT) to induce PH (Table 2a). The MCT model has been
invaluable for PH research, but it may be questioned
whether rats with MCT-induced PH die from progressive
PH, from RV failure or from other organ dysfunction [18].
Besides MCT, other models mimicking PH have been de-
veloped, e.g., hypoxia (with or without VEGF inhibitor
SUGEN) or the induction of increased pulmonary blood
flow [22–25]. Although all these models may represent
pulmonary vascular disease adequately, the potential direct
effects of the triggers used to induce PH on the RV limit
their use to study the pathobiology of RVF.
The pulmonary artery banding model (PAB) avoids these
limitations of the PH models (Table 2). The banding of the
pulmonary artery induces no systemic or toxic effects, and
the fixed constriction of the banding ensures a constant
afterload, also when pulmonary vasodilators are adminis-
tered. The time course of the phenotype in this model has
shown considerable variability, which may stem from dif-
ferences in strain, growth rate and size of constriction. Mild
constriction will lead to a chronically compensated state
with increased RV systolic pressure and RV hypertrophy,
but no symptoms of RV failure [16, 26, 27]. Rats have been
reported to survive up to 22 weeks in such condition, despite
(near) systemic RV pressures [28]. However, a tighter PAB
has been demonstrated to lead to clinical symptoms of RV
failure, i.e., inactivity, decreased cleaning behavior (raised
fur), poor peripheral circulation, dyspnea/tachypnea, ascites
and pleural/pericardial effusions and, ultimately, mortality
in a high percentage of animals [17, 29–31]. High-intensity
exercise capacity [32] and voluntary low-intensity exercise
[8, 16, 17] are reduced in this model. These data indicate that
a well-sized PAB represents a valuable model of chronic
pressure load-induced RV failure.
The physiology of RV adaptation to increased
afterload
The RV response to increased afterload shares several
features among all in vivo animal models used. The gold
standard to assess the hemodynamic properties of the
(loaded) RV is pressure–volume analysis, which allows
measurement of several parameters that quantify systolic
and diastolic function regardless of loading conditions.
The primary response of the RV to match increased
afterload is increased contractility, which is defined as
Table 1 Evaluation of RV disease in animal models
Parameter Examples
Type of loading Proximal pressure load (e.g., pulmonary artery banding)
Peripheral pressure load (e.g., pulmonary hypertension)
Volume load (e.g., aorto-caval shunt, pulmonary/tricuspid valve regurgitation)
Combined pressure/volume load (e.g., pulmonary hypertension ? aorto-caval shunt
Clinical symptoms Appearance (decreased grooming or inactivity)
Bodyweight changes (cachexia or fluid retention)





Effusion at autopsy Pleural effusion
Ascites
Liver wet/dry weight ratio
Survival Mortality
Human endpoints reached
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Table 2 Overview of hemodynamic changes in models of RV pressure load
Species Model Signs and
symptoms
Survival Exercise RVP EDP Ees Ees/Ea Eed CI or CO EDV Ref Remark
Peripheral pressure load
Rat mct30 None No mortality n/a 27 56 21 = -16 9 13 S [36]
Rat mct80 ;BW, inactivity No mortality n/a 67 S 38 15 ; -9 -26 89 S [36]
Rat mct80 Yes (see R1) No mortality V ; 96 S 199 S 188 S n/a 4 -8 30 [17] R1, R2
Rat mct60 ;BW, resp distress : mortality n/a 166 S 200 S 400 S ; 700 S -60 S n/a [34]
Rat mct60 n/a n/a n/a 325 S n/a 766 S = 500 S -64 S n/a [102]
Rat mct40 None No mortality F ; 120 S 400 S n/a n/a n/a -45 S n/a [56]
Rat mct60 Yes (see R3) n/a F ; 180 S 650 S n/a n/a n/a -10 n/a [56] R3
Rat mct60 n/a n/a F ; 140 S 333 S n/a n/a n/a -30 S 19 [32]
Rat mct60 n/a n/a n/a 160 S 200 S n/a n/a n/a -25 S n/a [27]
Rat mct60 n/a n/a n/a 110 S n/a n/a n/a n/a -60 S n/a [69]
Rat mct40 n/a n/a n/a 110 S n/a n/a n/a n/a -29 S n/a [103]
Rat mct40 n/a n/a n/a 121 S n/a n/a n/a n/a -39 S n/a [99] R4
Rat SuHx n/a n/a F ; 200 S n/a n/a n/a n/a -63 S n/a [32]
Rat SuHx n/a : mortality F ; 222 S n/a n/a n/a n/a -42 S n/a [88]
Rat SuHx n/a No mortality n/a 208 S n/a n/a n/a n/a -42 S n/a [28] R5
Rat SuHx n/a n/a n/a 283 S n/a n/a n/a n/a n/a n/a [66]
Rat FHR n/a n/a F ; 36 n/a n/a n/a n/a -42 S n/a [104]
Rat mct80 ; BW No mortality n/a n/a n/a n/a n/a n/a -50 S 25 S [51]
Rat mct60 n/a n/a n/a n/a n/a n/a n/a n/a -83 S n/a [105]
Rat mct60 n/a n/a n/a 126 S n/a n/a n/a n/a n/a n/a [106]
Rat mct60 n/a n/a n/a 130 S n/a n/a n/a n/a n/a n/a [107]
Rat mct60 Yes (see R6) : mortality n/a 133 S n/a n/a n/a n/a n/a n/a [108] R6
Rat mct60 Yes (see R7) : mortality n/a 133 S n/a n/a n/a n/a n/a n/a [109] R7
Rat mct60 n/a : mortality n/a 133 S n/a n/a n/a n/a n/a n/a [110]
Rat mct80 Yes (see R8) No mortality n/a n/a n/a n/a n/a n/a n/a n/a [37] R8
Rat mct30 none No mortality n/a n/a n/a n/a n/a n/a n/a n/a [65]
Rat mct80 Yes (see R9) No mortality n/a n/a n/a n/a n/a n/a n/a n/a [65] R9
Rat mct60 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a [94]
Rat mct60 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a [98]
Rat mct60 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a [83]
Pigs AVS n/a No mortality n/a 29 S n/a -13 ; n/a -44 S n/a [81] R10
Pigs AVS n/a No mortality n/a 84 S n/a 74 S = n/a 3 n/a [39] R11
Proximal pressure load
Lamb pab[ 8 None No mortality n/a 433 S 75 281 S n/a 62 S -37 S -13 [42] R12
Rabbit pab5 None No mortality n/a 271 S 30 S 185 S n/a 62 n/a n/a [58]
Dog pab13 n/a No mortality n/a 105 S n/a 243 S n/a 116 S 0 n/a [41]
Rat pab4 Mild symptoms No mortality V ; 169 S 500 S 162 S n/a 125 S -15 S 60 S [16]
Rat pab8 ABCDE (see R13) : mortality n/a 204 S 300 S 338 S ; 1053 S -50 S n/a [43] R13
Rat pab6 None n/a n/a 117 S 40 100 S n/a n/a -5 -18 [26]
Rat pab12 None n/a n/a 97 S 50 9 n/a n/a -25 S n/a [111] R14
Rat pab20 None n/a n/a 113 S 17 -9 n/a n/a -12 n/a [111] R15
Rat pab3 n/a n/a n/a 166 S 200 S n/a n/a n/a -26 S n/a [27]
Mouse pab4 None No mortality V ; 300 S n/a n/a n/a n/a 0 20 S [8]
Rat pab4 n/a n/a F ; 220 S n/a n/a n/a n/a -53 S n/a [32]
Rat pab7 n/a n/a n/a 152 S n/a n/a n/a n/a -37 S n/a [69]
Rat pab6 Yes (see R16) No mortality n/a 200 S n/a n/a n/a n/a 0 n/a [86] R16
Rat pab6 n/a n/a n/a 217 S n/a n/a n/a n/a n/a n/a [66]
Rat pab22 n/a No mortality n/a n/a n/a n/a n/a n/a 0 n/a [28]
Mouse pab3 n/a n/a n/a n/a n/a n/a n/a n/a 0 75 S [38]
Rat pab4 n/a n/a F ; n/a n/a n/a n/a n/a -42 S n/a [15]
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end-systolic elastance (Ees) (Table 2). Contractility in-
creases proportionally with increased arterial elastance (Ea,
reflecting afterload) to maintain stroke volume (Fig. 1a, b:
typical example of PV loops in response to pressure load).
When end-systolic elastance increases less than arterial
elastance, the Ees/Ea ratio decreases leading to ven-
tricular–arterial uncoupling, which is regarded a physio-
logical sign of RV failure. Indeed, beneficial
pharmacological effects in the pressure-loaded RV are not
seldom accompanied by a restoration of Ees/Ea ratio [16,
33, 34].
In chronic pressure load induced by pulmonary artery
constriction or experimental PH, increased contractility
[35] is accompanied by ventricular dilatation (Fig. 1b; [8,
16, 17, 32, 36–38]). This suggests that also the Frank–
Starling mechanism contributes to the RV adaptation to
chronic pressure load. Indeed, in most animal models of
chronic increased pressure load, ventricular dilatation is
associated with decreased Ees/Ea ratio, with the exception
of mild monocrotaline-induced PH [36] and 3-month du-
ration of flow-induced PH [39]. Unfortunately, ventricular
dilatation leads to increased wall stress [8, 40] and is
proposed as a hallmark of the failing ventricle [5], rather
than an adaptive response. Improvement of the RV–PA
coupling ratio does universally lead to reduction in RV
dilatation (Table 3) and wall stress.
Evidence is accumulating that RV failure due to chronic
pressure load is characterized by both enhanced systolic
function and progressive deterioration of diastolic function
[16, 31, 34]. Sparse clinical data show that in PH patients,
higher right atrial pressure (an indirect measure of RV
diastolic function) is associated with worse outcome. This
could indicate that diastolic dysfunction contributes to RV
failure in patients. From experimental models [41–44] us-
ing PAB as afterload (Table 2), it is clear that diastolic
dysfunction is an inherent component of increased RV
afterload (Fig. 1c, d; [17]). In dogs with a PAB, the dias-
tolic dysfunction of the RV is partly compensated for right
atrial adaptation, i.e., right atrial contractility increases, and
the right atrium dilates to serve as a reservoir [41]. In a
recent study in rats with a PAB separating those with
clinical signs of severe RV failure from those without
clinical signs but with RV dysfunction, clinical signs of RV
failure were associated with a further deterioration of di-
astolic function despite increased systolic function [31].
These observations are confirmed by studies on isolated
myocytes from patients with end-stage RV failure due to
PH [45]. Intriguingly, in a recent study in which the RV
was subjected to isolated volume load (pulmonary valve
regurgitation), diastolic dysfunction was described without
changes in Ees [46]. Deterioration of diastolic function
might thus play a central role in the transition from com-
pensation to failure (Fig. 1).
Diastolic function has a passive and an active compo-
nent. The RV (compared to the LV) has been suggested to
be particularly vulnerable to disturbed active relaxation,
possibly due to insufficient expression of the sodium-cal-
cium exchanger (NCX) [47]. Indeed, in experimental
Table 2 continued
Species Model Signs and
symptoms
Survival Exercise RVP EDP Ees Ees/Ea Eed CI or CO EDV Ref Remark
Rat pab6 n/a No mortality n/a n/a n/a n/a n/a n/a 0 n/a [28]
Rat pab8 n/a n/a F ; n/a n/a n/a n/a n/a -45 S n/a [15]
Rat pab lowcu n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a [28]
Rat pab3 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a [50]
Rat pab6 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a [50]
Mouse pab6 Yes (see R17) : mortality n/a n/a n/a n/a n/a n/a n/a n/a [29] R17
Rat pab9 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a [50]
Numbers are percentages increase/decrease versus controls. For some studies and parameters, these are approximations depending on how
precise data were reported. S indicates a significant change versus controls. Number behind ‘MCT’ indicates the dosage of monocrotaline in mg/
kg. Number behind ‘PAB’ indicates number of weeks after which measurements were performed
MCT monocrotaline, PAB pulmonary artery banding, FHR fawn-hooded rat, SuHx Sugen–Hypoxia, AVS arterio-venous shunt, BW bodyweight,
RVP right ventricular peak or systolic pressure, EDP end-diastolic pressure, Ees end-systolic elastance, Ea arterial elastance, Eed end-diastolic
elastance, CI cardiac index, CO cardiac output, EDV end-diastolic volume
*for exercise V indicates voluntary exercise testing, F indicates forced exercise testing; ; = decreased; : = increased; == unchanged
Remarks: R1 Some weight loss, inactivity and dyspnea. R2 V; was trend (p = 0.08). R3[ 5 % loss of body mass a day, lethargy, cyanosis,
respiratory distress. R4 CO estimated on ventricular diameters. R5 Pericardial fluid on echo; mortality steeply increased after 6 weeks. R6/R7
BW loss[ 10 % for 2 days and arterial oxygen saturation\80 %. R8 ‘signs of heart failure including pleural effusion and ascites’. R9 Weight
loss, pleural effusion, ascites. R10/R11 Hemodynamic measurements after shunt clamping. R12 Duration of PAB varied, but exceeded 8 weeks.
Eed is stiffness constant. R13 All ABCDE categories (see Table 1). R14/R15 CO is very low in these studies. R16 Failure symptoms are not
defined. R17 Failure symptoms were: edema, bodyweight changes (both : and ;). EDP was 300 S after 10 days in the tightest PAB group
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MCT-induced PH, active relaxation is increasingly dis-
turbed with increasing MCT dose [36], while passive
stiffness has been reported as normal [17, 36] or increased
[48]. Chronic PAB invariably leads to diastolic dysfunc-
tion, with disturbances in both active relaxation and passive
stiffness [16, 17, 41, 42].
Studies without pressure–volume analysis
Interpretation of the data in the literature is hampered by
the lack of pressure–volume analysis in many studies. The
alternatives, CMR-derived RV volumes or echocardio-
graphic parameters for systolic function, only indirectly
relate to contractility and are dependent on pre- and/or
afterload. Systolic displacement of the lateral tricuspid
annulus along the base-apex axis (TAPSE) is decreased in
chronic pressure load. This reflects reduced longitudinal
movement of the RV, but does not relate to RV pumping
function, i.e., shifting volume at a certain pressure [49].
Fractional shortening of the RV outflow tract [29] and
change in surface area [50] are also reported, but their
significance in the setting of abnormal RV loading is un-
known. CMR, the gold standard for RV function in clinical
practice, has the advantage of being noninvasive, but
without simultaneous pressure measurements, only yields
load-dependent variables [8, 51, 52]. RV ejection fraction
(EF), another outcome parameter, is generally reduced
before overt RV failure ensues, although this parameter is
of limited value as it is preload dependent [8, 36]. As de-
scribed above, PV analysis characterizes the initial RV
response as increased contractility and ventricular dilata-
tion, two processes that have opposite effects on EF.
Depending on the relative size of changes, EF may thus be
increased, decreased or remain unchanged. Recently,
Vanderpool et al. [53] suggested RV stroke volume divided
by the end-systolic volume as an alternative, less preload
dependent parameter.
Proximal- versus peripheral-type pressure load
Whether the type of pressure load (PAB vs. PH) determines
the RV response is a matter of debate as conflicting data
have been reported. Echocardiographic data suggest that at
similar levels of pressure overload, the RV is less dilated
and has superior function in patients with pulmonary
stenosis compared with those with PAH. In contrast, a
recent experimental comparison between rats with PAB
and PH [17] showed that the PAB rats with moderate RV
dysfunction (assessed by exercise and clinical signs and
symptoms) had more severe RV dilatation in response to
afterload than rats subjected to MCT-induced PH.
Interaction with LV function
The RV and LV functionally interact via shared fibers and
the interventricular septum [11]. Interaction of the pres-
sure-loaded RV with LV function has been noted in pa-
tients and animal models with PH [54, 55]. In a study in
isolated hearts from rats with MCT-PH, pacing improved
RV function and reduced interference in the diastolic phase
[56]. Also, studies in isolated hearts suggested that the LV
contributes to 65 % of the work of the normal RV [57]. In a
PAB rabbit model of moderate RV dysfunction, increasing
LV afterload via aortic constriction improved systolic RV
function [58]. End-diastolic elastance tended to increase,
but this effect was not significant.
The increased knowledge on the functional charac-
terization of RV response to increased afterload leads to the
question: Can we manipulate this response to support the
failing RV? To answer this question, the hemodynamic
adaptation has to be coupled to the pathobiology.
Fig. 1 Pathophysiology of the pressure-loaded RV. Conceptual
representation of the progression of pathophysiological changes in
the pressure-loaded RV. Typical pressure–volume (PV) loops from
compensation to failure. Volumetric changes were derived from
experimental studies and extrapolated using previously published
normal values. Straight lines represent the end-systolic elastance
(Ees), dotted lines represent the end-diastolic elastance (Eed). a PV
loop in the unloaded RV, showing normal systolic and diastolic
function. b PV loop in compensated RV, showing increased systolic
function (Ees) and RV dilatation (increased end-diastolic volume) but
normal diastolic function (Eed). c PV loop in transition to failure
showing increased systolic function (Ees) and impaired diastolic
function (Eed). d PV loop in RV failure showing increased or pseudo-
normalized systolic function (Ees) and further impaired diastolic
function (Eed)
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Pathobiology of RV failure
In the pressure-loaded RV, a myriad of cellular changes
takes place that may initially serve as adaptive remodeling,
but are also present in the failing RV (Fig. 2). Rather than
caused by a single ‘malignant’ pathway, RV failure is the
resultant of many biological changes, both adaptive and
maladaptive. The interpretation of these changes is influ-
enced by the state of RV dysfunction assessed by clinical
signs and hemodynamic measurements as well as the
trigger inducing the afterload (e.g., MCT or PAB). Some of
these changes resemble those found in LV remodeling in
adaptation to stress [40, 59].
RV hypertrophy, isoform switch and fibrosis
RV hypertrophy is an adaptive response to reduce wall
stress and improve contractility. In the LV, hypertrophy is
a strong predictor for outcome [59], but in experimental
RV failure, this relation is less clear. In all studies in ex-
perimental animals, RV hypertrophy is present but this is
not related to functional adaptation [16, 17, 26, 28]. In one
study, RV hypertrophy was more severe in a PH model
than in a PAB model [28], in other studies it was not,
possibly due to differences in the degree of loading [14, 17,
26]. This is important to note, as some authors compare
different models using the degree of RV hypertrophy to
classify the state of adaptation, which may yield contra-
dictory results [15].
Increased afterload of the RV induces a switch in myosin
heavy chain (MHC) isoform composition from the fast
alpha-MHC to the slower but energetically favorable beta-
MHC in the RV myocardium [8, 16, 17, 27]. This response
is not related to the degree of RV dysfunction. The hy-
pertrophic response is induced by similar pathways as in
the LV, e.g., the calcineurin-NFAT pathway [8], which
may render the RV a putative target for calcineurin inter-
ference or other therapeutic strategies that have been
shown to target LV hypertrophy [20].
RV fibrosis in response to increased afterload has been
reported in some PH models [28, 34, 60] as well as in PAB
models [17, 28], although there is a wide variation in the
amount of collagen measured across models and the
timeframe in which it develops. Given the putative relation
between fibrosis and diastolic dysfunction, fibrosis may be
a therapeutic target. However, a recent study shows there
was no relation between the amount of (interstitial
myocardial) fibrosis and the degree of RV dysfunction
Fig. 2 Overview of the pathobiological changes in the abnormally
loaded RV. Pathobiological hallmarks of the abnormally loaded RV.
A myriad of genetic and epigenetic changes result in tissue damage-
related processes (oxidative stress, fibrosis and apoptosis) and
activation of (mal)adaptive processes on the tissue (capillary forma-
tion, inflammation) or cellular level (hypertrophy, energy substrate
use, mitochondrial function and calcium handling). These processes
are regulated by a complex network of signaling pathways related to
contactile function, cellular growth, energy metabolism and neuro-
humoral signaling. ATP adenosine triphosphate, NFAT nuclear factor
of activated T cells, MAPK mitogen-activated protein kinase, Mef2
myocyte enhancer factor-2, PKG-1 protein kinase G-1, PDE3/5
phosphodiesterase-type 3/5, PKA protein kinase A, SERCA2 sar-
coplasmic reticulum Ca2 ? -ATPase, RyR ryanodine receptor, PLB
phospholamban, NCX sodium-calcium exchanger, SP3 transcriptional
repressor SP3, RAAS renin angiotensin aldosterone system
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[17]. One may hypothesize that RV fibrosis is a by-product
of the (mal)adaptive RV response to pressure load and has
limited pathophysiological significance. Either way, fibro-
sis can be reduced with several interventions, i.e., beta-
blockade [34], ROS scavenger [51], prostacyclin [60], but
whether this is a direct effect or secondary to afterload
reduction is unclear. Interestingly, an effective strategy to
target specifically fibrosis (in LV failure) did not reduce
fibrosis nor improve RV function in experimental RV
failure [43]. Fibrosis may thus have ventricular-specific
characteristics that require further exploration of its
pathophysiological significance and therapeutic amen-
ability in RV failure.
RV capillary formation/RV oxygen supply
Capillary rarefaction can play an important role in the
development of RV failure. In the unstressed RV, coronary
perfusion is present throughout the cardiac cycle [10], but
in patients with PH, the coronary perfusion occurs pri-
marily during diastole [61]. Because RV oxygen con-
sumption also increases; a chronic oxygen demand–supply
mismatch may be an underlying mechanism in the transi-
tion to failure. Coronary flow has not been measured yet in
experimental models, but capillary density was reduced in
several PH models [28, 34, 60]. Recently, two studies in
various pressure load-induced disease states, i.e., MCT [14]
and PAB [31], reported increased capillary density in
compensated RV hypertrophy and pseudo-normalized
density in decompensated RV hypertrophy. Further support
for the significance of insufficient myocardial perfusion
comes from the observation that prostacyclin therapy in
rats with PH improves both capillary density and survival
in the absence of beneficial effects on pulmonary hemo-
dynamics or vascular remodeling [60]. Given its putative
importance in the pathophysiology of RV failure, it is
questioned which cellular processes are most affected by
reduced myocardial perfusion. Candidate pathways are
substrate metabolism, mitochondrial function and calcium
handling.
Cardiac metabolism
In the LV, significant shifts in myocardial metabolism have
been reported during the transition from adaptation to
failure. Fatty acids are the main substrate for the adult heart
under normal conditions, but under stress, a switch in
substrate use occurs toward glucose and lactate [62]. In
addition, glucose metabolism shifts from complete oxida-
tion via the Krebs cycle to glycolysis only, which yields
less ATP but also uses less oxygen per ATP molecule.
Metabolic shifts are also observed in the pressure-loaded
RV. Fatty acid oxidation (FAO) is reduced in PH patients,
but only in those with severe hypertrophy [63]. Also, in rats
with MCT-induced PH, the expression of CPT-1b (a rate
limiting enzyme in the uptake of long-chain fatty acids
[64]) was reduced [65, 66]. A reduction in the use of fatty
acids seems to be an adaptive mechanism, since preventive
inhibition via trimetazidine (which inhibits an essential
step in oxidation of FA), increased cardiac output measured
by echocardiography in a model of mild RV dysfunction
due to a PAB [15].
In addition to the reduction in FAO, patients with PH
have an increased uptake of the glucose analog 18FDG in
the RV [67]. Also, in rats with MCT-induced PH, the ex-
pression of glycolysis-related genes is increased [68] as
well as the enzymatic rates of glycolysis [69]. Increased
expression of glycolysis-related genes has been shown in
rats with MCT-PH [69], hypoxic-PH [70], Fawn-Hooded
rats [71] and rats with a PAB [15, 69, 72], but none of the
rats in these experimental studies had clinical symptoms of
RV failure. Similarly, upregulation of pyruvate dehydro-
genase kinase (PDK), which uncouples glycolysis from the
Krebs cycle, has been shown in both PH and PAB models
of adaptive RV remodeling [71]. Inhibition of PDK has
been shown to increase RV O2 consumption and improve
RV function, although a concomitant reduction in RV
systolic pressure in the setting of fixed afterload (PAB
model) in this study complicated the interpretation of these
results [71]. Further evaluation of these effects in models of
more severe RV dysfunction is needed since this therapy
has also been shown to reverse pulmonary vascular re-
modeling in experimental PH [73], which could indicate a
therapeutic strategy that may benefit both the RV and
pulmonary vasculature.
Mitochondrial function
Mitochondria are the ‘‘powerhouses’’ of the cardiomy-
ocyte, but also regulate many processes involved in the
response to stress: formation of oxygen radicals, oxygen
sensing, induction of apoptosis and inflammation [74]. The
first notion that the RV in PH may be subjected to in-
creased ‘‘oxidative stress’’ came from observations in rats
with MCT-induced PH. These rats had increased myocar-
dial activity of complex II and oxygen radicals, and also
increased production of radical scavengers [37]. Treatment
with a radical scavenger (EUK-134) improved RV systolic
function but did not affect diastolic dysfunction [51];
however, in this study, pulmonary vascular resistance was
also decreased after EUK-134 treatment, which may have
contributed to the beneficial RV effects [75]. In another PH
model (SUGEN ? hypoxia), treatment with protandim (a
plant extract inducing nrf2 expression) increased cardiac
output, suggesting that at least in PH rats, increasing de-
fense mechanisms against oxidative stress may be
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beneficial [28]. These pathways have not been tested in
PAB models, i.e., independent from the pulmonary
circulation.
Apoptosis and inflammation
Apoptosis and inflammation, both important mechanisms
in the vascular pathology of PH [76–78], have not been
explored in detail in the myocardium of models of RV
pressure load. However, cardiomyocyte apoptosis and in-
flammation have been reported in both PH and PAB
models [58, 79–81]. Pressure load is linked to apoptosis in
multiple ways (mechanic damage, oxidative stress and
neurohumoral signaling) and even mildly increased rates of
apoptosis can contribute to heart failure [40]. Inflamma-
tion, marked by the presence and activation of immune
cells and increased activity of inflammatory cytokines also
connects pressure load and apoptosis. In addition, in LV
pressure, mediators such as TNF-alpha and interleukins
interact with neurohumoral signaling, induce fibrosis and
affect contractile function and myocardial gene expression
[40]. Data on the functional importance of inflammation in
the development of RV failure are lacking.
PKG2PDE5 pathway
The importance of the protein kinase G (PKG) and phos-
phodiesterase 5 (PDE5) pathway in LV remodeling was
shown in mice with transverse aortic constriction [82].
PDE5 catabolizes cGMP, which activates PKG and gen-
erally suppresses proliferative pathways. Hence, PDE5
inhibitors (e.g., sildenafil) may enhance the protective ef-
fects of PKG. Patients with increased RV afterload showed
increased PDE5 expression [83], but only few studies in rat
report data on PDE5 expression or PKG activity. PKG
activity is not uniformly lowered in all models of ex-
perimental RV afterload [16]. Therefore, currently little is
known about the importance of this pathway in RV failure.
Positive results of intervention studies targeting this
pathway (see Treatment of RV failure below) underline the
importance of more detailed exploration of the PKG-
PDE5 pathway in the RV as it may provide new treatment
options for RV failure.
Other pathways
What are the consequences of the unique embryologic
origin of the RV for the response to stress [8, 84]? In a rat
model of PAB, the expression of dHand, an RV-specific
precursor, as well as GATA-4, MEF2 and NKX2.5 were
increased [85]. On the other hand, also signaling pathways
involved in LV remodeling, such as the calcineurin path-
way, have been shown to be activated in a murine model of
PAB [8]. However, suppression of calcineurin activation in
transgenic mice induced RV dilatation even without pres-
sure load [20]. Similarly, inhibitors of histone deacytelases,
which reduce adverse remodeling and improve function in
experimental LV pressure load, worsen RV function in rats
with a PAB [86]. Such incidental reports suggest that the
regulation of adaptation to stress is indeed (partly) chamber
specific.
The use of microarrays yields divergent results on genes
and pathways possibly involved in the development of RV
failure [31, 38, 65, 72, 87]. This may be due to the dif-
ferences in models used (e.g., MCT vs. PAB), species
differences (rat, mouse and rabbit) and different degrees of
RV adaptation (compensated vs. decompensated). Addi-
tionally, array studies have provided evidence for chamber
specificity of gene expression. Table 4 provides a summary
of differences in signals between RV and LV in response to
increased afterload.
A study in mice, comparing pressure load of the RV via
PAB with pressure load of the LV via aortic constriction,
showed differences between the two ventricles in expres-
sion of genes involved in (1) extracellular matrix proteins,
(2) proteases and inhibitors and (3) developmentally
regulated proteins [38]. In a similar study, four microRNAs
were upregulated in the pressure-loaded RV, but these were
Table 4 Differences in signals between RV and LV in response to increased afterload
Model Mechanism Difference with LV Ref
Mouse PAB Extracellular matrix proteins : expressed in RV [38]
Proteases and inhibitors : expressed in RV [38]
Developmentally regulated proteins only expressed in RV [38]
Rat PAB PINK1 ; in RVF, : in LVF [31, 114]
Mouse PAB vs TAC miRNA 28,148a,93 : in RVF (in non-myocyt fraction) [87]
Mouse PAB Wnt signalling :: in RVF[LVF [29]
Rat MCT Mef2c : compensated RV, ; RVF, no change LVF [115]
Overview of studies reporting differences in myocardial signaling between the RV and LV, in response to increased afterload
PAB pulmonary artery banding, TAC transverse aorta constriction, RVF RV failure, LVF LV failure
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all located in the non-myocyte fraction of the RV [80].
Gain/loss of function studies is the next step to determine
the functional relevance of these findings.
Treatment of RV failure
Currently, no RV-specific medical treatment strategies
exist. Reports of experimental RV drugs (Table 3) fall into
one of three categories: (1) treatment strategies for LV
failure (e.g., beta-adrenergic blockade, RAAS inhibition),
(2) drugs that target the pulmonary vasculature in PH (e.g.,
PDE5 inhibitors, endothelin antagonists) and (3) proof-of-
concept studies with experimental treatments.
Beta-adrenergic blockade and RAAS inhibition
The cornerstones of treatment of LV failure are inhibition
of the beta-adrenergic receptors and the renin-angiotensin
aldosterone system (RAAS). Clinicians are reluctant to
prescribe beta blockers to patients with failing RVs in the
setting of PH because of their negative inotropic effects,
but preclinical studies have shown beneficial effects on RV
remodeling. In the hypoxia ? SUGEN model of PH, car-
vedilol, a non-selective beta blocker with also alpha-1-
receptor blocking effects, reduced the development of hy-
pertrophy, fibrosis, capillary rarefaction and attenuated
reduction in cardiac output and TAPSE [88]. After treat-
ment with Metoprolol, a selective beta blocker, similar
effects were observed, although these can be attributed to
reduction in the pulmonary vascular remodeling [88]. In
the MCT model, bisoprolol (another selective beta blocker)
does not prevent hypertrophy or capillary rarefaction, but
prevents fibrosis along with delaying the decline in cardiac
output and TAPSE [34]. Interestingly, bisoprolol increased
phosphorylation of myocardial titin, suggesting a direct RV
effect. In conclusion, beta blockers have variable effects in
PH models. Unfortunately, no data are published on beta-
blockade in the failing RV due to stenosis-type pressure
overload, which might elucidate the direct protective ef-
fects of beta-blockade on the RV.
Clinical data in PH suggest that the RAAS is activated
in at least a subgroup of patients. There are also sugges-
tions that the RAAS system is active in congenital heart
disease, and that combinations of RAAS-inhibiting drugs
that are used in the standard care for LV failure patients
(such as angiotensin receptor blockers ? eplerenone)
might potentiate the effect and target oxidative stress, fi-
brosis and improve diastolic dysfunction like in the LV.
However, recently no effect of RAAS inhibition was
Fig. 3 Effects of sildenafil depend on the stage of pressure load-
induced RV dysfunction sildenafil effects in the early (0–4 weeks)
and late (4–8 weeks) stage of pressure load-induced RV dysfunction
are compared. These data illustrate the concept that the effects of
pharmacological intervention in the pressure-loaded RV (in these
studies with sildenafil) depend on the stage of RV failure when
treatment is started. Data of rats with a PAB at week 4 are derived
from [16], in which sildenafil treatment was started at the day of
surgery (preventive strategy); data of rats with PAB at week 4–8 are
derived from [44], in which sildenafil treatment was started 4 weeks
after the PAB surgery, when RV dysfunction was already present
(therapeutic strategy). a End-systolic elastance (Ees). b End-diastolic
elastance (Eed). To allow comparison of Eed between the studies, the
Eed of the initial 2 mmHg end-diastolic pressure drop during
occlusion was used here (see methods on characterization of diastolic
function). c Permillage RV fibrosis per unit surface area. d Ejection
fraction. Mean ± SEM, * p\ 0.05. PAB pulmonary artery banding,
VEH vehicle treated, SIL sildenafil treated. Figure adapted from [44];
used without permission
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shown in a rat model of PAB [43], in accordance with the
results from a study in patients with a systemic RV in CHD
[89].
PDE5 inhibitors
PDE5 inhibition would be an excellent therapeutic ap-
proach for RV failure in PH, as it also reduces pulmonary
vasculature resistance [90]. However, the first two studies
reporting on PDE5 inhibition in the PAB model showed no
prevention or reduction in hypertrophy and fibrosis [27,
50]. In these studies, the functional analysis was limited to
thermodilution-measured cardiac output and echocar-
diography. Using pressure–volume analysis, it was shown
that preventive sildenafil increases contractility, reduces
dilatation and attenuates the decline of spontaneous exer-
cise, but leaves diastolic function unchanged [16], whereas
in established RV pressure load, sildenafil treatment pre-
dominantly improved diastolic dysfunction, with a small
effect on contractility [44]. The differences between the
first and the latter studies may be due to differences in the
severity of the loading condition, as in the LV it was shown
that the effects of PDE5 inhibition are dependent upon the
severity of the loading condition [91].
The mechanisms by which sildenafil exerts its effects
are pleiotropic, incompletely known and not limited to the
PDE5-PKG system. Mechanistically, sildenafil inhibits
PDE5, increases compartmentalized cGMP and thereby
activates PKG-1, which in turn has inhibitory effects on
pathways of pathological remodeling [92]. PKG-1 also
phosphorylates titin, thereby reducing stiffness [93]. In the
pressure-loaded RV, sildenafil treatment as a preventive
strategy increased fibrosis [16, 27, 50]. However, when
given in a later stage of established pressure load, sildenafil
reduced fibrosis and reduced ventricular stiffness [44],
supporting the concept that timing and loading severity
determines cardiac response (Fig. 3). Sildenafil also sti-
mulates the PDE3-PKA pathway and targets mitochon-
drial (k)ATP channels, mitochondria and inflammation
[94]. Other pharmacological approaches to manipulate the
PDE5-PKG-1 axis include stimulation of soluble guany-
late cyclase by riociguat, but results so far indicate effects
on the pulmonary vasculature, rather than direct beneficial
RV effects [95].
Endothelin receptor antagonists
Endothelin receptor antagonists (ERA) have an anti-
hypertrophic and anti-fibrotic effect on the RV in PH [96].
It is unclear whether this is a direct effect on the RV or a
consequence of the vasodilatation and anti-proliferative
effect on the pulmonary vasculature. Unfortunately, no
studies have addressed this issue. Endothelin-1 increases
contractility in mouse RV cardiomyocytes via an increase
in intracellular Ca2? transients through activation of the
Endothelin Receptor-A and the Na?–Ca2? exchanger [97].
Upregulation of endothelin-1 in RV myocardium of pa-
tients and models of compensated hypertrophy [98] sug-
gests a potential rationale for ERAs. However, isolated
heart studies showed that ERAs suppress both contractility
and relaxation in the hypertrophic RV [98] which might
explain the negative outcomes of preclinical studies on
ERAs in RV pressure load without pulmonary vascular
remodeling [99]. Intriguingly, the negative inotropic effect
of ERAs is absent in LV failure, which may be due to
differences in endothelin-1 activation. It may even be
possible that ERAs have contrasting therapeutic effects in
compensated and failing RVs, but so far, this has not been
studied.
Apart from medical intervention, exercise training may
be beneficial for the pressure-loaded RV. In patients with a
pressure-loaded RV, exercise training induces a modest
increase in exercise capacity [100]. In rats with MCT-in-
duced PH; however, exercise training was beneficial in
mild PH and deleterious in severe PH [101]. Exercise
training has not been tested yet in other models of RV load.
Conclusion
Since the Working Group Statement, progress has been
made in understanding the pathophysiological and patho-
biological mechanisms of RV failure due to chronic ab-
normal loading conditions, specifically increased afterload.
The RV adaptation to increased afterload is characterized
by increased contractility, dilatation and hypertrophy,
whereas clinical RV failure is associated with progressive
diastolic deterioration and despite increased contractility,
disturbed ventricular-arterial coupling. The pathobiology
of the failing RV has several characteristic features. An
important factor seems to be the lack of adequate increase
in capillary density leading to a hypoxic environment and
oxidative stress. Additionally, there is a metabolic switch
from FA to glucose utilization in the process of RV
adaptation, but the role of this switch in RV failure is yet
unclear. So far, therapies aiming to specifically improve
RV function have had limited success. The use of beta
blockers and sildenafil may hold some promise, but new
therapies have to be developed. Finally, a lot of insight has
been gained with regard to the specific values and limita-
tions of the different models of RV pressure load and the
methods used to define and characterize RV function and
failure. In the future, this may aid in the understanding of
the pathobiology of RV failure and development of new
therapeutic strategies.
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